DRUG
OBE022
Oral
Status
Unknown
Phase
Phase 2
Enrollment
115
Locations
18
Results
Not posted
Publications
1
Study summary
This is a proof-of-concept study in 2 parts. In Part A, patients will receive OBE022 open-label in order to assess the safety and pharmacokinetics in pregnant women with spontaneous preterm labour with a gestational age between 28 0/7 and 33 6/7 weeks. Part B has a double-blind, randomised, placebo controlled, parallel group and multicentre design and will assess the efficacy, safety and pharmacokinetics in pregnant women with threatened spontaneous preterm labour with a gestational age between 24 0/7 and 33 6/7 weeks. All patients in part A and part B must receive atosiban infusion for 48 hours as standard of care treatment. Patients from Part A will receive OBE022 open label. Patients from Part B will be randomised to receive OBE022 or matching placebo. IMP treatment duration will be up to 7 days. IMP treatment will be stopped in case of delivery prior to Day 7.
Interventions
DRUG
Oral
DRUG
Oral
DRUG
I.V.
Timeline
First posted
Dec 11, 2017
Study start
Jan 10, 2018
Primary completion
Jul 8, 2020
Study completion
Aug 2022
Results posted
Not reported
Registry updated
Jun 7, 2021
Outcomes
Incidence of delivery within 2 days (48 h) from start of IMP administration
Time frame · 48 hours
Incidence of delivery within 7 days (168 h) from start of IMP administration
Time frame · 168 hours
Incidence of delivery before 37 weeks of GA
Time frame · Up to 13 weeks from start of IMP administration
Time to delivery measured from start of IMP administration
Time frame · Up to 17 weeks from start of IMP administration
Not reported in the indexed record.
Eligibility
Key Inclusion Criteria: Part A * Pregnant females aged ≥ 18 years * Patients with a singleton or twin pregnancy * Gestational age between 28 0/7 and 33 6/7 * Administered or prescribed atosiban for the treatment of preterm labour Part B * Pregnant females aged ≥ 18 years * Patients with a singleton or twin pregnancy * Gestational age between 24 0/7 and 33 6/7 * Administered or prescribed atosiban for the treatment of preterm labour * ≥4 uterine contractions per 30 minutes * Cervical dilatation of 1 to 4 cm inclusive * At least one of the following signs of preterm labour: 1. positive IGFBP-1 or fœtal Fibronectin test 2. cervical length ≤ 25mm 3. progressive cervical change Key Exclusion Criteria: * Fœtal death in utero in current or previous pregnancy after gestational week 24 or expected high risk of fœtal death in the coming days * Oligohydramnios * Known pathological Doppler ultrasound of the umbilical artery * Any contraindications for the mother or the fœtus to stop labour or prolong pregnancy or any maternal or fœtal conditions likely to indicate iatrogenic delivery in the next 7 days, including but not limited to: 1. Premature rupture of membranes 2. Evidence or suspicion of abruptio placenta 3. Signs and/or symptoms of chorio-amnionitis 4. Pre-eclampsia, eclampsia or HELLP-syndrome * Use of cervical cerclage in the current pregnancy or a pessary in situ * Current use of anti-hypertensive medication * Treatment with other tocolytics within specified time before the baseline assessment of uterine contractions
Study locations
Czechia · Finland · Israel · Russia · Spain · Vietnam. Showing up to 24 locations stored in the fast local snapshot.
Gynekologicko-porodnická klinika Fakultní nemocnice Brno
Brno, Czechia
Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze
Prague, Czechia
Ústav pro péči o matku a dítě
Prague, Czechia
Helsinki Universisty Hospital
Helsinki, Finland
Hilel Yafe Medical Center, Maternal Fetal Unit
Haifa, Israel
Rambam Medical Center, Maternal Fetal Unit
Haifa, Israel
Meir Medical Center, Obstetrics and Gynecology Department
Kfar Saba, Israel
Rabin Medical Center, Fetal-Maternal Medicine, Helen Schneider's Hospital for Women
Petah Tikva, Israel
Moscow Regional Perinatal Center
Balashikha, Russia
Kazan State Medical University
Kazan', Russia
City clinical hospital № 15 named after O. M. Filatov of Healthcare Department of Moscow
Moscow, Russia
Perinatal center of the City Clinical Hospital #24
Moscow, Russia
Hospital La Paz
Madrid, Spain
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia, Spain
Hospital Clínico Universitario de Santiago
Santiago de Compostela, Spain
Hospital Universitari i Politècnic La Fe
Valencia, Spain
Hanoi Obstetrics and Gynecology Hospital
Hanoi, Vietnam
My Duc Hospital
Ho Chi Minh City, Vietnam
Related trials
Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Infertility
Not applicable
Recruiting
792
2025-12
University of Electronic Science and Technology of China · Healthy Adult Male
Early Phase 1
Recruiting
250
2025-09
University of Electronic Science and Technology of China · Healhty
Early Phase 1
Recruiting
250
2025-07
Children's Hospital of Chongqing Medical University · Cervical Cerclage · Premature Birth
Not applicable
Completed
334
2025-05
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Preterm Birth
Phase 4
Completed
760
2024-07
University of Sao Paulo General Hospital · Myelomeningocele · Terbutaline Adverse Reaction
Not applicable
Completed
25
2022-06
Radboud University Medical Center · Endometriosis
Phase 2
Unknown
10
2022-05
Al Baraka Fertility Hospital · Recurrent Implantation Failure
Not applicable
Unknown
150
2021-09
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.